Interview: Why this biotech chose the ASX over the NASDAQ

Imagion Biosystems is a biotech company aiming to make a difference to the lives of cancer patients, with groundbreaking imaging techniques being trialled in Australian hospitals.

CEO Bob Proulx joins Sean Aylmer from San Diego to talk about Imagion's work, and why they chose to list on the ASX.

Find out more: https://fearandgreed.com.au/

See omnystudio.com/listener for privacy information.